Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Antithrombin Deficiency

Interventions

DRUG: Human plasma derived antithrombin
DRUG: Placebo

Sponsor

Octapharma